Johnson & Johnson (JNJ) is a publicly traded Healthcare sector company. As of May 20, 2026, JNJ trades at $230.00 with a market cap of $551.06B and a P/E ratio of 26.42. JNJ moved -0.35% today. Year to date, JNJ is +12.24%; over the trailing twelve months it is +49.24%. Its 52-week range spans $140.68 to $251.71. Analyst consensus is buy with an average price target of $264.75. Rallies surfaces JNJ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Johnson & Johnson Reports Darzalex, Tremfya Growth with AAA Rating, 64-Year Dividend Streak: J&J spun off its consumer healthcare segment and posted rising Darzalex and Tremfya sales, while its expanding oncology pipeline and new drug approvals fuel growth. The company maintains a AAA credit rating higher than the U.S. Government and a 64-year dividend streak despite risks from patent expirations and talc litigation.
| Metric | Value |
|---|---|
| Price | $230.00 |
| Market Cap | $551.06B |
| P/E Ratio | 26.42 |
| EPS | $8.73 |
| Dividend Yield | 1.34% |
| 52-Week High | $251.71 |
| 52-Week Low | $140.68 |
| Volume | 3.37M |
| Avg Volume | 0 |
| Revenue (TTM) | $96.36B |
| Net Income | $21.04B |
| Gross Margin | 67.82% |
18 analysts cover JNJ: 0 strong buy, 12 buy, 6 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $264.75.